

### This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Disease models</b>			
Mouse model of Epstein-Barr virus (EBV)-driven B cell lymphoma	Mice that express EBV latent membrane protein 1 (Lmp-1) in B cells could aid the development of new treatments for EBV-associated lymphoma. In the mice, T cell depletion led to the formation of Lmp-1 <sup>+</sup> tumors including diffuse large B cell lymphoma. In immunodeficient mice injected with Lmp-1 <sup>+</sup> tumor cells derived from the model, a fusion protein containing the extracellular domain of killer cell lectin-like receptor subfamily K member 1 (Klrk1; Cd314; Nkg2d) and an Fc fragment of mouse IgG2a decreased tumor growth compared with control protein. Preclinical studies to evaluate the Nkg2d-Fc fusion protein are ongoing.	Patent application filed covering fusion protein; licensing information available from the Dana-Farber Cancer Institute Office of Research and Technology Ventures	Zhang, B. <i>et al. Cell</i> ; published online Feb. 17, 2012; doi:10.1016/j.cell.2011.12.031 <b>Contact:</b> Klaus Rajewsky, University of Cologne, Cologne, Germany e-mail: <a href="mailto:klaus.rajewsky@mdc-berlin.de">klaus.rajewsky@mdc-berlin.de</a>
	<b>SciBX 5(9); doi:10.1038/scibx.2012.238</b> Published online March 1, 2012		